A new study looking at the ICU admission rates of Covid-19 patients in hospitals has revealed that cannabis users were less likely to end up in the ICU. The study looked at two hospitals in Los Angeles and found both lower admission rates (12% vs. 31%) and shorter hospitalizations (4 days vs. 6 days) for regular cannabis users. It is not the first study to find benefits from cannabinoids.
A new study published in the Journal of Cannabis Research found that cannabis users experienced less severe Covid-19 cases in hospitals than non-cannabis users. Cannabis users had better outcomes, including reduced need for ICU admissions and intubation.
For more news like this, download our free cannabis news app.
Covid-19 Study Details
The study involved two hospitals in the Los Angeles area of California. Of the 1,831 Covid-19 patients in the study, 69 patients reported regular use of cannabis, which was just 4% of all patients.
“The link between cannabis use and better Covid outcomes is reasonable,” the authors say. However, the authors also admit that their study was minimal and that any conclusions are only suggestions. The study authors analyzed patient data from the NIH Covid-19 Severity Scores database, including the need for oxygen supply, admission to the intensive care unit, mechanical ventilation, hospitalization length, and hospital death among cannabis and non-cannabis users.
Cannabis Users Outperformed Non-Users
“Cannabis users outperformed non-users, reflecting better overall outcomes, shorter hospitalization (4 days vs. 6 days), lower ICU admission rates (12% vs. 31%), and less need for mechanical ventilation (6% vs. 17%). ICU admissions were 12 percentage points lower, and intubation rates were six percentage points lower in cannabis users, ‘the study reads.
The study suggests that regular cannabis use may positively affect the course of Covid-19 in hospitalized patients. The authors hypothesize that the better outcomes may be due to the therapeutic properties, including the anti-inflammatory effects of specific cannabinoids.
“Cannabis users were more likely to have lower levels of inflammation on admission compared to non-users. This effect was sustained during the hospital stay, and cannabis users on discharge had lower markers of inflammation compared to non-users,” the study reads.
Covid-19 Study Demographics
The cannabis users participating in this study were typically younger, 62% male and 38% female, and the majority were white (48%), with 15% Black, 4% Asian, and 28% Hispanic. In addition, 20% of cannabis users are tobacco smokers compared to just 4% of all patients.
This study is not the first to look at the positive effects of cannabinoids on Covid-19, although it is the first to compare data from actual Covid patients who have been admitted to the hospital. One widely publicized study found that the cannabinoids CBGA and CBDA prevent infection and shorten the duration of the disease. Other research suggests that CBD alleviates Covid-19 symptoms and regenerates the lungs after the condition has passed.
DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published by Fakty Konopne, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions, or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.